Alcediag
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
May 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (US 10,323,283) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Jul 16, 2027The maintenance fee for Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects (US 11,873,531) comes due Jul 16, 2027. Unpaid by Jan 18, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,771,953 | Evaluation of the potential risk of drug induced mood disturbance and suicide: use of a dedicated platform In force · From the USPTO record | In force | From the USPTO record | |
| US 10,323,283 | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects In force · From the USPTO record | In force | From the USPTO record | |
| US 10,851,420 | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects In force · From the USPTO record | In force | From the USPTO record | |
| US 11,873,531 | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects In force · From the USPTO record | In force | From the USPTO record | |
| US 12,084,719 | RNA editing as biomarkers for mood disorders test In force · From the USPTO record | In force | From the USPTO record | |
| US 12,596,125 | Nano-Rheological Biomarkers for Early and Improved Follow-Up of Pathologies Associated to RBC Deformability Alteration In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 1 abandoned · 2 no status recorded